Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00052944" target="_blank" >RIV/00216224:14110/11:00052944 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11150/11:10107273 RIV/61989592:15110/11:10224234 RIV/65269705:_____/11:#0001577 RIV/00179906:_____/11:10107273 RIV/00023736:_____/11:00010136

Result on the web

<a href="http://dx.doi.org/10.4149/neo_2011_03_256" target="_blank" >http://dx.doi.org/10.4149/neo_2011_03_256</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/neo_2011_03_256" target="_blank" >10.4149/neo_2011_03_256</a>

Result language

angličtina

Original language name

Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia

Original language description

Tyrosine kinase inhibitors (TKI) have completely changed the prognosis of patients with Ph+ chronic myeloid leukemia (CML). The occurrence of a second malignancy (SM) in CML patients successfully treated with TKI may significantly affect their prognosis.In a retrospective study of 1,038 patients with CML treated at 10 centers in the Czech Republic and Slovakia between 2000 and 2009, SM was detected in 35 (3.37%) patients after TKI therapy was initiated. The median intervals from the diagnosis of CML and from the start of TKI therapy to the diagnosis of SM were 58 months (range 2 - 214) and 32 months (range 1 - 102), respectively. The observed age-standardized incidence of SM after the start of TKI therapy was 8.95 / 1,000 person-years. Comparison of the incidence of SM in CML patients with population data was performed only for patients from the Czech Republic. The age-standardized incidence rate of all malignant tumors except non-melanoma skin cancers was 6.76 (95% CI: 6.74; 6.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2011

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Neoplasma

ISSN

0028-2685

e-ISSN

—

Volume of the periodical

58

Issue of the periodical within the volume

3

Country of publishing house

SK - SLOVAKIA

Number of pages

7

Pages from-to

256-262

UT code for WoS article

000290695800012

EID of the result in the Scopus database

—